

MELOXIWAY ORAL SUSPENSION FOR DOGS

For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

ACTIVE CONSTITUENT:

1.5 mg/mL Meloxicam

NET CONTENTS:

10 mL
32 mL
100 mL

DIRECTIONS FOR USE:

Use as directed by prescribing veterinarian

CLAIMS:

For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

Meloxiway Oral Suspension is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as discospondylosis, arthropathy and soft tissue injuries.

Meloxicam is a non-steroidal anti-inflammatory compound of the oxacam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leukocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

CONTRAINDICATIONS:

The use of the product is contraindicated in animals suffering from cardiac, hepatic or clinical renal disease. This is also the case where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product.

Do not administer to pregnant or lactating bitches in the last third of pregnancy.

As for all NSAIDs use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

Meloxiway Oral Suspension should not be administered concurrently with steroidal or other nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics or anti-coagulant agents. Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Meloxiway Oral Suspension. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously.

DOSAGE & ADMINISTRATION:

SHAKE WELL BEFORE USE.

Discard 6 months after initial use when stored below 25°C (air conditioning).



To be administered orally. Either mix with a small amount of food, then, once eaten, follow with the remainder of normal ration, or administer directly into the mouth. On the first day of treatment a single dose of 0.2 mg/kg body weight should be given. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at maintenance dose of 0.1 mg/kg body weight.

If no improvement is noticeable after 10 days of treatment, please consult a veterinary surgeon. For longer term treatment, once clinical response has been observed (after 4 days), the dose of Meloxiway Oral Suspension for Dogs can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculoskeletal disorders may vary over time. Should longer term treatment be contemplated, the prescribing veterinarian should observe current best practice including, but not limited to, regular monitoring of relevant clinical and biochemical parameters.

GENERAL DIRECTIONS:

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) compound of the oxicam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic. It inhibits leukocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen-induced thrombocyte aggregation.

PRECAUTIONS:

Meloxiway Oral Suspension for Dogs should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics or anticoagulant agents. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Meloxiway Oral Suspension for Dogs. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously.

Response to a long-term therapy should be monitored at three monthly intervals or more frequently as advised by the veterinarian.

Meloxiway Oral Suspension for Dogs should not be used following parenteral injection of Meloxicam or any other NSAID as appropriate dosage regimens for such follow-up treatments have not been established.

The use of this product in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

SIDE EFFECTS:

Typical adverse reactions of NSAIDs may occur (particularly within the first week of treatment).

These may include loss of appetite, vomiting, diarrhoea, faecal occult blood and lethargy. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects are in most cases transient and disappear following termination of treatment but in very rare cases may be serious. If side effects are persistent or of severity, treatment should be discontinued, and the advice of the veterinarian should be sought. In case of overdosing a symptomatic treatment should be initiated.

SAFETY DIRECTIONS:

Harmful if swallowed. May irritate the eyes and skin. Avoid contact with eyes and skin. When using this product wear disposable gloves. Wash hands after use.



FIRST AID INSTRUCTIONS:

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 13 11 26.

ADDITIONAL USER SAFETY:

Pregnant women and people with known hypersensitivity to NSAIDs should avoid contact with meloxicam. If the medicine comes into contact with the skin, the affected area should be rinsed thoroughly.

DISPOSAL

Dispose of container by wrapping in paper and putting in the garbage.

STORAGE

Store below 25°C (air conditioning).

APVMA Approval No. 90137/135599

